AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Medicine intangible by Year
Medicine intangible — Amolyt Pharma (eneboparatide) ($M) ($M)
AstraZeneca Medicine intangible: $861M in FY2025, up 12.1% from a year earlier.
Latest, FY2025
861
Period ended Dec 31, 2025
Change on a year earlier
+12.1%
768 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Intangible asset products in development arising from the acquisition of Amolyt Pharma SAS 1 | | 861 | | Not amortised |”
Reported in Form 20-F Note 10/11 — Significant Intangible Assets.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Medicine intangible — Amolyt Pharma (eneboparatide) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 861 | +12.1% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 768 | – | Form 20-F FY2024 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca Medicine intangible ($M), annual FY2024–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/intang-med-amolyt
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.